Program
ruzinurad
Also written as “SHR4640”, “SHR4640 tablet” and “SHR4640 dose1”.
Its studies are mostly in Hyperuricemia · Gout, led by Jiangsu HengRui Medicine.
Drug pageRuzinurad: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 201 open or running | phase 3since Aug 6, 2019 | Apr 27, 2016 | Jul 2027phase 2 · NCT07362355 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Apr 27, 2016.
- Jun 27, 2017Phase 1 study in GoutNCT03211403 · 24 enrolled · Australia
- Aug 6, 2019Phase 3 study in GoutNCT04052932 · 594 enrolled · China
- Nov 4, 2019Phase 1 study in HyperuricemiaNCT04157959 · 28 enrolled · China
- Nov 26, 2019Phase 2 study in HyperuricemiaNCT04180982 · 84 enrolled
- Jan 20, 2020Phase 1 study in Healthy Adult Male VolunteersNCT04260373 · 6 enrolled · China
- Mar 10, 2020Phase 1 study in Hepatic ImpairmentNCT04305392 · 24 enrolled · China
- Sep 27, 2020Phase 1 study in HyperuricemiaNCT04586803 · 24 enrolled
- Nov 3, 2020Phase 1 study in Healthy SubjectsNCT04620408 · 14 enrolled
- Apr 19, 2021Phase 1 study in Healthy Male SubjectsNCT04850638 · 18 enrolled · China
- Jul 7, 2021Phase 3 study in GoutNCT04956432 · 779 enrolled · China
- Jul 28, 2021Named ruzinuradINNProposed as its International Nonproprietary Name in WHO's List 125 · before, SHR4640
- Aug 22, 2022Phase 2 study in HyperuricemiaNCT05513976 · 129 enrolled
- Jul 13, 2023Phase 1 study in HyperuricemiaNCT05954169 · 16 enrolled · China
- Dec 5, 20232 phase 1 studiesNCT06168929, NCT06196580
- Jan 15, 2026Phase 2 study in HyperuricemiaNCT07362355 · 340 planned · China
Ahead
- Jul 2027Primary completion: phase 2 study in HyperuricemiaNCT07362355
TargetBeta
“Solute carrier family 22 member 12 inhibitor”ChEMBL 37, by rule
Other programs on SLC22A12
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| dotinuradrule | fuji-yakuhin-co-ltd | phase 3 | 22 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07362355Hyperuricemia · China | 2 | Recruiting | Jul 2027 | 340 |
| NCT06196580Gout · China | 1 | Completed | Feb 16, 2024 | 24 |
| NCT06168929Hyperuricemia · China | 1 | Completed | Jan 13, 2024 | 34 |
| NCT05954169Hyperuricemia · China | 1 | Completed | Jul 1, 2024 | 16 |
| NCT05513976Hyperuricemia | 2 | UNKNOWN | May 30, 2023 | 129 |
| NCT04956432Gout · China | 3 | Completed | Dec 13, 2023 | 779 |
| NCT04850638Healthy Male Subjects · China | 1 | Completed | Sep 5, 2021 | 18 |
| NCT04620408Healthy Subjects | 1 | UNKNOWN | Jan 2021 | 14 |
| NCT04586803Hyperuricemia | 1 | UNKNOWN | Nov 2020 | 24 |
| NCT04305392Hepatic Impairment · China | 1 | UNKNOWN | Dec 2022 | 24 |
| NCT04260373Healthy Adult Male Volunteers · China | 1 | Completed | Apr 3, 2020 | 6 |
| NCT04180982Hyperuricemia | 2 | UNKNOWN | Jul 30, 2020 | 84 |
| NCT04157959Hyperuricemia · China | 1 | UNKNOWN | Jun 1, 2020 | 28 |
| NCT04052932Gout · China | 3 | Completed | Jul 14, 2021 | 594 |
| NCT03211403Gout · Australia | 1 | Completed | Feb 15, 2018 | 24 |
| NCT03185793Hyperuricemia · China | 2 | Completed | Jul 20, 2018 | 198 |
| NCT03131583Gout · China | 1 | Completed | Jan 29, 2018 | 15 |
| NCT03015948Gout · Australia | 1 | Completed | Nov 23, 2016 | 40 |
| NCT02890966Gout · China | 1 | Completed | Feb 2017 | 48 |
| NCT02815839Gout · China | 1 | Completed | Feb 2017 | 50 |
How it is read
Names in the registry
- “SHR4640”, 15 entries
- “SHR4640 tablet”, 2 entries
- “SHR4640 dose1”, 2 entries
- “SHR4640 ;Febuxostat”, 1 entry
- “SHR4640 ; Febuxostat”, 1 entry
Codes read as this program: SHR4640.
Conditions, from the studies’ own filings
- Hyperuricemia, 8 studies
- Gout, 8 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.